The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
02-Sep-22
Pending
$205 million
Target:
brsk
Acquiror:
Ares Management
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
01-Jun-22
$537 million
Target:
NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital
Acquiror:
Azorra Aviation
Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital
05-May-22
Undisclosed
Target:
Airtower Networks
Acquiror:
DIF Capital Partners
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
08-Apr-22
$364 million
Target:
Netomnia
Acquiror:
DigitalBridge Investment Management, Advencap, SoHo Square
Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited
15-Nov-21
$166 million
Target:
Netomnia
Acquiror:
Avenue Capital, Advencap
Advised Netomnia, a UK-based fibre operator, on its first large-scale fundraise of £123m
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
10-Sep-20
$195 million
Target:
Saga plc
Acquiror:
Sir Roger De Haan
Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise
12-Nov-18
$84 million
Target:
AUB Group Limited
Advised ASX-listed AUB Group, a leading insurance intermediary business operating a network of over 100 insurance brokers and underwriting agencies across Australia and New Zealand, on its fully underwritten entitlement offer to raise A$116mm
02-Nov-18
$NA
Target:
Pinnacle Midstream
Acquiror:
EagleClaw Midstream
Advised I Squared Capital on the contribution of Pinnacle Midstream, its Delaware Basin Midstream Company, to EagleClaw Midstream as part of the formation of a leading Delaware Basin Midstream Partnership with EagleClaw Midstream and Blackstone Energy Partners
28-Sep-18
$NA
Target:
Blue Sky Alternative Investments Limited
Acquiror:
Oaktree Capital Management L.P.
Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility
28-Sep-18
$NA
Target:
Grupo Monge
Advised Grupo Monge, a leading Latin American retailer and consumer finance company, in the establishment of a long-term funding relationship with impact investment manager BlueOrchard
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
29-Nov-17
$NA
Target:
Substantially all of the gas production and midstream assets of Energy Corporation of America
Acquiror:
Greylock Energy
Advised Energy Corporation of America, a natural gas producer focused on the Marcellus Shale, on the sale of substantially all its gas production and midstream assets to Greylock Energy, an affiliate of ArcLight Capital Partners
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
26-May-16
$500 million
Target:
Apex International Energy Management LLC
Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
31-Jul-13
$NA
Target:
CPP Group plc
Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments